Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

PERTZYE

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

Standard Dose
90,750USP UNITS;24,000USP UNITS;86,250USP UNITS
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview PERTZYE is listed in Drugs@FDA under application 022175 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) Form and strength CAPSULE, DELAYED RELEASE;ORAL - 90,750USP UNITS;24,000USP UNITS;86,250USP UNITS Sponsor DIGESTIVE CARE INC Submission history Latest submission status date: 2024-02-28 00:00:00.

Structured Monograph

Clinical summary

Approval overview PERTZYE is listed in Drugs@FDA under application 022175 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) Form and strength CAPSULE, DELAYED RELEASE;ORAL - 90,750USP UNITS;24,000USP UNITS;86,250USP UNITS Sponsor DIGESTIVE CARE INC Submission history Latest submission status date: 2024-02-28 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.